Investigation Report on Chinese Pregabalin Market, 2018-2022

$2200$3300

It is estimated that Pfizer’s Lyrica will continue to dominate the Chinese market from 2018 to 2022 but its market share will decline because of the price competition of China-made Pregabalin.

SKU: 1807309 Category: Tag:

Description

Description
Pregabalin is a new-generation drug for neuralgia treatment. In Jul. 2004, it was approved by the European Union to treat some epileptic seizures in adults. In Dec. 2004, it was approved by the U.S. Food and Drug Administration (FDA) to treat diabetic peripheral neuralgia and postherpetic neuralgia. In 2006, generalized anxiety disorder and social anxiety disorder became new indications of Pregabalin. In 2007, Pregabalin was approved by the FDA as the first drug to treat fibromyalgia syndrome. In 2012, Pregabalin was approved by the FDA to treat spinal cord injury (SCI)-related pains. In 2010, Lyrica was approved to enter China.
According to CRI, the sales value of Lyrica increased by more than 200 times from about CNY 200,000 in 2010 to over 40 million in 2017. Due to Lyrica’s success, many domestic manufacturers applied for Pregabalin production. Chongqing Succeway Pharmaceutical Co., Ltd.’s Pregabalin (trade name: Lairuike) was put in the market after obtaining the production license in 2013 and is gradually taking market share from Pfizer. By sales value, in 2017, Pfizer’s Lyrica had a market share of approximately 79.8%, and the rest market share was captured by the products of Chongqing Succeway Pharmaceutical Co., Ltd. It is estimated that Pfizer’s Lyrica will continue to dominate the Chinese market from 2018 to 2022 but its market share will decline because of the price competition of China-made Pregabalin.
There is a continuous rise in the number of people suffering from indications for Pregabalin. For example, the number of epileptics in China has exceeded 10 million and increases by 400,000 every year. Therefore, Pregabalin has a bright prospect in China.

Topics Covered:
– Development environment of Chinese Pregabalin market
– Governmental approval of Pregabalin in China
– Prices of Pregabalin in China
– Major Pregabalin manufacturers in China
– Factors influencing the development of Chinese Pregabalin market
– Prospects of Chinese Pregabalin market

Related reports:

Investigation Report on China’s Pregabalin Market 2021-2025

 

Additional information

Publisher

Geography Covered

Date Published

Pages

Charts

Format

Table of Contents

Table of Contents

1 Relevant Concepts of Pregabalin
1.1 Indications for Pregabalin
1.2 Development History of Pregabalin in China
1.3 Governmental Approval of Pregabalin in China

2 Sales of Pregabalin in China, 2013-2017
2.1 Sales Value of Pregabalin in China
2.1.1 Overall Sales Value
2.1.2 Sales Value by Region
2.2 Sales Volume of Pregabalin in China
2.2.1 Overall Sales Volume
2.2.2 Sales Volume by Region
2.3 Analysis on Dosage Forms of Pregabalin

3 Major Pregabalin Manufacturers in China, 2013-2017
3.1 Analysis on Major Manufacturers
3.1.1 Market Share by Sales Value
3.1.2 Market Share by Sales Volume
3.2 Pfizer
3.2.1 Enterprise Profile
3.2.2 Sales of Pfizer’s Pregabalin in China
3.3 Chongqing Succeway Pharmaceutical Co., Ltd.
3.3.1 Enterprise Profile
3.3.2 Sales of Chongqing Succeway Pharmaceutical Co., Ltd.’s Pregabalin in China

4 Prices of Pregabalin in China, 2017-2018
4.1 Averages Prices of Pregabalin in China
4.1.1 National Average Price
4.1.2 Average Price by Region
4.2 Prices of Major Manufacturers’ Pregabalin in China
4.2.1 Pfizer (Lyrica)
4.2.2 Chongqing Succeway Pharmaceutical Co., Ltd. (Lairuike)

5 Prospects of Chinese Pregabalin Market, 2018-2022
5.1 Factors Influencing Pregabalin Development in China
5.1.1 Driving Forces and Market Opportunities
5.1.2 Threats and Challenges
5.2 Generic Drugs
5.3 Forecast on Market Size of Pregabalin in China, 2018-2022
5.4 Forecast on Competition Pattern of Pregabalin in China

Selected Charts
Chart Pregabalin Products Approved to Market in in China by 2018
Chart Sales Value of Pregabalin in China, 2013-2017
Chart Sales Value of Pregabalin by Region in China, 2013-2017
Chart Market Share of Pregabalin Manufacturers by Sales Value in China, 2013-2017
Chart Price of Pfizer’s Pregabalin in China, 2017-2018
Chart Price of Chongqing Succeway Pharmaceutical Co., Ltd.’s Pregabalin in China, 2017-2018
Chart Forecast on Sales of Pregabalin in China, 2018-2022